Sarcopenic obesity in type 2 diabetes: An underrecognized clinical challenge Published: 2026 To the editor, We read with considerable interest the recent article by Limpaarayakul et al. examining the prevalence and determinants of sarcopenic obesity among Thai individuals with type 2 diabetes mellitus (T2DM) [1]. The study addresses a clinically significant yet under-recognized phenotype that embodies the complex interplay between metabolic dysfunction, aging, and adverse body composition. The reported prevalence of 16.4% provides important region-specific insight; however, it appears lower than estimates from broader Asian cohorts, where prevalence has been reported to approach 26% [2]. This discrepancy underscores a persistent challenge in the field—namely, the heterogeneity in diagnostic criteria for both sarcopenia and obesity. As emphasized by the ESPEN and EASO consensus, the absence of standardized definitions continues to limit comparability across studies and may obscure the true global burden of sarcopenic obesity [3]. In this context, the authors’ use of adiposity-based criteria rather than body mass index is commendable and aligns with evolving recommendations favoring more precise body composition assessment. Importantly, the identification of advancing age and reduced calf circumference as independent risk factors, alongside the protective role of handgrip strength, is biologically plausible and consistent with established pathophysiological mechanisms. Accumulating evidence suggests that T2DM accelerates muscle catabolism through insulin resistance, chronic low-grade inflammation, and mitochondrial dysfunction, thereby predisposing individuals to sarcopenic obesity [4,5]. These findings reinforce the growing consensus that muscle strength and function are critical, yet often overlooked, components of metabolic health. Nevertheless, several methodological considerations warrant further discussion. The cross-sectional design precludes causal inference and limits the ability to delineate temporal relationships between metabolic derangements and changes in body composition. Moreover, the single-center, urban-based sampling framework raises concerns regarding external validity, particularly in light of potential rural–urban disparities in lifestyle, nutrition, and healthcare access. The exclusion of patients with significant comorbidities, while methodologically justifiable, may further introduce selection bias and lead to underestimation of disease burden in real-world clinical settings. Despite these limitations, the study makes a meaningful contribution to the expanding literature on sarcopenic obesity in T2DM and highlights the urgent need for routine screening strategies incorporating functional and compositional measures. Future investigations employing longitudinal, multicenter designs and standardized diagnostic frameworks will be essential to advance understanding, refine risk stratification, and inform targeted interventions. CRediT author statement AJ- Conceptualization, Editing & reviewing draft, Writing original draft. MA- Supervision, Editing & reviewing draft. DS: Writing original draft. Declaration of generative AI and AI-assisted technologies in the writing process The authors declare that AI-based language assistance was used solely for grammar refinement. All intellectual content, interpretation, and conclusions are the sole responsibility of the authors. Funding and disclosures None. Declaration of competing interest We all authors declare no competing interests.